NCT00479583 - Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Cancer

Interventions

DRUG

BMS-690514 / FOLFIRI

Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos

DRUG

BMS-690514 / FOLFOX

Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos

Trial Locations (4)

19111

Fox Chase Cancer Center, Philadelphia

35294

University Of Alabama At Birmingham, Birmingham

44805

Local Institution, Saint-Herblain

94805

Local Institution, Villejuif